ストックスクリーナーアプリを入手
1.40
0.71%
-0.01
Dogwood Therapeutics Inc (DWTX) 最新ニュース
H.C. Wainwright reiterates Dogwood Therapeutics stock rating at buy - Investing.com
H.C. Wainwright reiterates Dogwood Therapeutics stock rating at buy By Investing.com - Investing.com Australia
H.C. Wainwright reiterates Dogwood Therapeutics stock rating at buy By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Dogwood Therapeutics stock rating at buy By Investing.com - Investing.com India
H.C. Wainwright reiterates Dogwood Therapeutics stock rating at buy By Investing.com - Investing.com Canada
H.C. Wainwright reiterates Dogwood Therapeutics stock rating at buy By Investing.com - Investing.com UK
Dogwood Therapeutics advances Halneuron for che... - Pluang
Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment - TradingView
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Dogwood Therapeutics Nears Phase 2b Readout for Halneuron Neuropathic Pain Treatment - Yahoo Finance
Dogwood (DWTX) Earnings Reading: The Available Earnings Metric Delivers a Beat in the Current Update; After Earnings: Shares Finish 6.87% Up in the Latest ReadingHigh Estimate Range - vinanet.vn
Dogwood (DWTX) Update: Records a 6.87% Increase to $2.49 at the Close; Boundary Watch: the Supplied Trading Band Runs From $2.37 to $2.61 in the Latest SessionImpulse Wave - vinanet.vn
Armistice Capital Expands Dogwood Therapeutics Stake Amid Biotec - GuruFocus
Dogwood (DWTX) Quarterly Results: EPS Lands Above Forecast; Market Move: Shares Move 7.79% Lower on the DayTax Rate Impact - vinanet.vn
Dogwood (DWTX) Earnings Reading: Profit Per Share Clears Its Benchmark in the Current Update; Latest Reaction - vinanet.vn
Research Analysts Offer Predictions for DWTX Q3 Earnings - MarketBeat
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026 - The Manila Times
Halneuron Has Been Tested on More Than 800 Patients—What’s Next? - Stock Titan
Dogwood to Host Virtual KOL Event to Discuss Halneuron® for the Treatment of Chemotherapy Induced Neuropathic Pain on September 1, 2026 - markets.businessinsider.com
What is HC Wainwright's Forecast for DWTX FY2029 Earnings? - MarketBeat
Dogwood Therapeutics, Inc. (NASDAQ: DWTX) Stock Price, News & Analysis - kalkine.ca
Dogwood Therapeutics, Inc. (NASDAQ: DWTX) Stock Price, News & Analysis - kalkine.com.au
Dogwood Therapeutics, Inc. 2026: Revenue ($14.06M), EPS ($0.34) — 10-Q Summary - TradingView
Dogwood Therapeutics (DWTX) logs $16.5M H1 loss and warns on going concern outlook - Stock Titan
Armistice Capital (DWTX) discloses 9.99% Dogwood Therapeutics ownership in 13G/A - Stock Titan
Maxim Group Maintains Dogwood Therapeutics(DWTX.US) With Buy Rating, Maintains Target Price $15 - Moomoo
Dogwood Therapeutics, Inc. (DWTX) EPS 2025: $7.13 loss per share - Stock Titan
Dogwood Therapeutics (NASDAQ:DWTX) Releases Earnings Results, Misses Estimates By $0.21 EPS - MarketBeat
Form 8K Dogwood Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria
Form 8K Dogwood Therapeutics Inc For: 13 August By Investing.com - Investing.com Canada
Form 8K Dogwood Therapeutics Inc For: 13 August By Investing.com - Investing.com India
Form 8K Dogwood Therapeutics Inc For: 13 August By Investing.com - Investing.com UK
Dogwood Therapeutics Reports $11.5 Million Second-Quarter Net Loss - Quiver Quantitative
Dogwood Therapeutics reports Q2 2026 net loss of $11.5M, IPR&D charge of $9.19M; $9.6M cash - TradingView
DWTX: Halneuron Phase 2b trial nears completion as Q2 net loss widens on higher R&D and impairment - TradingView
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results - The Manila Times
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results - Yahoo Finance
Dogwood Therapeutics Announces Second Quarter 2026 Financial Results - GlobeNewswire
Dogwood Therapeutics (DWTX) Rises 2.78% as Buyers Defend Key $1.76 SupportMAMA Signal - vinanet.vn
Dogwood Therapeutics Inc (DWTX) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dogwood Therapeutics Inc (DWTX) Stock News Today - TradingKey
Dogwood Therapeutics Inc expected to post a loss of 14 cents a shareEarnings Preview - TradingView
Dogwood Therapeutics (DWTX) to Release Quarterly Earnings on Wednesday - marketbeat.com
Dogwood Therapeutics (DWTX) Holds Steady at $1.79: Key Levels to Watch as Biotech Stock ConsolidatesDealer Gamma - vinanet.vn
Dogwood Therapeutics (NASDAQ:DWTX) Shares Up 4.3%What's Next? - MarketBeat
Dogwood Therapeutics posts corporate presentation on non-opioid pain, neuropathy drug pipeline - Bitget
Dogwood Therapeutics Inc (DWTX) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive Surprise - vinanet.vn
Dogwood Therapeutics Inc. (DWTX) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SurpriseRevenue Beat Analysis - dars.gov.et
Dogwood Therapeutics, Inc. Revenue Breakdown – NASDAQ:DWTX - TradingView
1.64%
0.29%
大文字化:
|
ボリューム (24 時間):